“Victoria leads the nation in mRNA expertise with universities, research institutes and industry working together to accelerate local mRNA development and manufacturing. We’ve acted swiftly to establish mRNA Victoria and committed $50 million to grow mRNA capability here, and we’re already making great
Colin Poulton, Professor of Pharmaceutical Biology, Monash University, shared his views about the new technology. He said, “This machinery will allow us to work with IDT Australia to produce our second-generation COVID-19 vaccine in preparation for Phase 1 clinical trials, which will be conducted through our partnership with the Doherty Institute.” progress.”
The Victorian government has pledged $5 million to fund the clinical studies, which will commence in October 2021 and will be led by the Monash Institute of Pharmaceutical Sciences. The preliminary findings are predicted to be out in the first half of 2022.
